Novel heterozygous compound TRMT5 mutations associated with combined oxidative phosphorylation deficiency 26 in a Chinese family: a case report

Combined oxidative phosphorylation deficiency 26 (COXPD26; MIM #616539), which includes developmental delay, shortness of breath, exercise intolerance, spasticity hyporeflexia, and hypotonia leading to the patient being unable to sit, stand, or walk without support, and decreased mitochondrial complex activity, is an autosomal recessive disorder characterized by a highly variable phenotype [1‐3]. COXPD26 was first characterized in 1989 by Haller et al. [1]. To date, only four COXPD26 cases from three unrelated families are described [1‐3]. Powell et al. reported a woman (the same case Haller et al. reported) and a 7-year-old boy, both of whom showed muscle weakness, exercise intolerance, neuropathy, gastrointestinal problems, spasticity with hyperreflexia, increased serum lactate levels, and decreased activity of mitochondrial complex IV. Over the following years, the woman developed exocrine insufficiency with malabsorption, liver cirrhosis, and renal tubulopathy. The boy showed additional features, including early-onset growth retardation, abnormal facial features, and hypertrophic nonobstructive cardiomyopathy. Mark reported two additional adult patients, both of whom had disease onset in childhood [2]. The patients presented similar aspects of the previously described phenotypes, including muscle weakness, exercise intolerance, neuropathy, and spastic diplegia [1‐3]. Prematurity and the global developmental delay of one case were similar to the symptoms of the 7-year-old boy. Shortness of breath upon exertion was observed in Patient 1, as well as in the previously reported woman [2] (Table 1).

TRMT5 (tRNA (guanine(37)-N1)-methyltransferase 5, NM_020810) is considered as the gene causing COXPD26 [1, 2]. TRMT5 is located on chromosome 14q23.1 and encodes a 509-amino-acid protein that is produced in the cytosol and then transported into the mitochondria [2]. In mitochondria, it aids in the modification of tRNA 1-methylguanosine (m¹G) at position 37, which is next to the 3′ end of the anticodon [4], both in vivo and in vitro [2]. Moreover, TRMT5 is not very specific with respect to the structure of bound tRNA which will be methylated [5]. In eukaryotes, about 11 kinds of tRNA can be modified with m¹G37 [6, 7]. The methylation helps in reading frame maintenance by protecting against frameshifting when the peptides are elongated on the mRNA. Otherwise, a +1 frameshift error may occur, causing premature termination of protein synthesis [8]. It is conceivable that defective production of essential proteins due to errors such as frameshifts will disturb cellular function. For example, disruption of the TRMT5 homologous gene TrmD in Salmonella typhimurium, Streptococcus pneumoniae, and Saccharomyces cerevisiae severely impairs microorganismal growth [9, 10]. In humans, when TRMT5 is transported into mitochondria, it methylates the tRNAs that are encoded by mitochondrial DNA (mtDNA) [11]. Altered tRNA methylation in mitochondria will affect the expression of proteins encoded by mtDNA and disturb respiratory function [1, 2]. This may be the pathogenic mechanism of COXPD26 caused by recessively inherited mutations in TRMT5. In this paper the first Chinese family with COXPD26 is described. We report a female patient with clinical features similar to previous cases of COXPD26 and a novel compound heterozygous mutation of TRMT5. The present study expands the currently available evidence concerning mutations associated with COXPD26.

The pedigree underwent careful physical examination. The proband’s parents (I:1, I:2) were nonconsanguineous and both appeared normal. The proband (II:1) had frequently suffered from pneumonia since she was born, accompanied with shortness of breath much of the time (Fig. 1A). As a neonate, she presented laryngeal stridor and was diagnosed with laryngomalacia. She began to experience nausea and vomiting after being fed when she was 2 months old, and a gastrostomy tube was placed at that time. She presented considerable tympanites and gastrointestinal dysmotility with frequent vomiting. When she was 6 months old, she could raise her head. She could sit at the age of 10 months and stand at the age of 2 years. Developmental delay was obvious at the age of 4 years, when she reached a height of only 98cm (<2SD). Unfortunately, the patient suffered from motor retardation. Furthermore, she was unable to sit or stand without help, let alone walk. Moreover, muscular hypotonia and exercise intolerance was evident. Her motor development, speech, and social adaptation were assessed to be 2.5 years delayed. She only could communicate with her family by facial expressions, gestures, and simple sounds even though she had normal visual and auditory abilities. Recurrent seizures appeared with spastic diplegia at 5 years of age. A prominent fast wave in the frontal lobe was observed by electroencephalogram examination. Brain magnetic resonance imaging (MRI) showed a wide extracerebral space (Fig. 1B) and thin corpus callosum (Fig. 1C). Muscle biopsy showed myopathic changes with different size and small diameter of muscle fibers (Fig. 1D), and increased lipid droplets (Fig. 1E). Additionally, hepatic biopsy followed by electron microscopy revealed abundant lipid droplets (Fig. 1F). Through light microscopy, diffuse hepatocellular steatosis was observed (Fig. 1G). Immunohistochemistry showed that the bile duct epithelium was positive for cytokeratin 19 (Fig. 1H) and a few activated Kupffer cells were positive for CD68 (Fig. 1I), and Masson staining revealed fibrous hyperplasia in the portal area (Fig. 1J). Due to intracytoplasmic accumulation of glycogen, the periodic acid-Schiff (PAS) reaction was positive (Fig. 1K) and the D-PAS reaction was negative (Fig. 1L). In addition, blood tests indicated mildly elevated alanine aminotransferase levels and a physical exam did not indicate hepatomegaly. There was an apparent renal defect with oliguria and elevated creatinine, urea nitrogen, and uric acid levels, so dialysis was employed. Inherited metabolic disorders were screened, and slightly elevated lactate levels in blood and urine were observed. Serum antibody tests for toxoplasma, rubella virus, cytomegalovirus, and herpes simplex virus were negative and the patient’s plasma ammonia levels, triglyceride levels, blood glucose levels, karyotype, auditory brainstem responses, and thyroid function were all normal. There was no cardiac involvement apart from tachycardia; cardiac troponin I and creatine kinase isoenzyme levels were also in the normal range (Table 2). The patient died from stroke and respiratory failure at the age of 5 years. According to the patient’s main symptoms, which were in accordance with the common features of COXPD26, a diagnosis of COXPD26 was made.

This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee (Children’s Hospital of Soochow University, No. 2019LW010). Written consent was obtained from the parents before they participated in the genetic investigation. To achieve an accurate genetic diagnosis, medical exome sequencing was carried out with a trio sample strategy. The advantages and experimental procedures of this technique were previously described by our team [12]. Novel heterozygous missense mutations in TRMT5 (NM_020810) were detected in the proband (Fig. 2), which were c.881A>C (p.E294A) from her mother and c.1218G>C (p.Q406H) and c.1481C>T (p.T494M) on the same chromosome from her father. The proband inherited these missense mutations in TRMT5, which made herself compound heterozygous. The c.881A>C (p.E294A) and c.1481C>T (p.T494M) mutations were reported with a minor-allele frequency of 0.0003 and 0.0008, respectively, in the Aggregation Consortium (ExAC) Browser. The c.1218G>C (p.Q406H) mutation had not been recorded in the ExAC Browser previously. The residue T494 was considered as a phosphorylated site according to the PhosphoSitePlus browser (https://​www.​phosphosite.​org/​homeAction.​action). The three mutated residues were all evolutionarily well conserved (Fig. 3A), which indicates these residues have important functions.

To explore whether the mutations could lead to protein misfolding, homologous models of truncated wild-type and mutated TRMT5 fragments including each mutated residue were generated. The peptides containing p.E294A and p.Q406H were modeled on SWISS-MODEL (https://​swissmodel.​expasy.​org/​). As SWISS-MODEL could only build the model from residue 96 to 469, we built the peptide model from residue 406 to 509 (which contained p.T494M) on QUARK (https://​zhanglab.​ccmb.​med.​umich.​edu/​QUARK2/​). The hydrogen bonds were analyzed by PyMOL (ver 1.4.1). There was one more hydrogen bond between R291 and the mutated residue A294 than between R291 and the wild-type E294 (Fig. 3B and C). Moreover, there were two more hydrogen bonds between the mutated residues H406 and D404 and S410 than between the wild-type Q406 and D404 and S410 (Fig. 3D and E), and there were two hydrogen bonds less between the mutated residues M494 and R491 and F498 than between the wild-type T494 and R491 and F498 (Fig. 3F and G). All of the alterations in hydrogen bonds might lead to misfolding of TRMT5 to affect its normal function. The bioinformatic analysis indicated these three mutations in TRMT5 were all associated with COXPD26.

Our case presented recurrent pneumonia, shortness of breath, gastrointestinal dysmotility with frequent vomiting, severe developmental delay, muscular hypotonia and exercise intolerance, and renal and hepatic defects. She was unable to sit or stand without help. In addition, her motor development, speech, and social adaptation were delayed, which is consistent with previous reports [1‐3]. Recurrent seizures with spastic diplegia appeared when she was 5 years old, which is consistent with Patient 2 in Mark’s article [3]. A wide extracerebral space and thin corpus callosum were indicated by brain MRI. Brain MRI of this disease is not specific, as each patient has different manifestations. Muscle biopsy showed myopathic features without ragged-red fibers, as was the case for the 7-year-old patient in Powell’s paper [2]. Muscle biopsy also indicated reduced respiratory chain complex enzyme activities. Unfortunately, the enzyme activity of COX could not be detected in our lab. However, liver pathology of this disease has not been reported in previous research. In the present study, light and electron microscopy indicated a large amount of glycogen and high fat accumulation in the liver, which likely led to liver damage with increased collagen deposition and Kupffer cell activation. Blood glucose levels were within the normal range, but the patient’s delayed motor development and exercise intolerance indirectly suggested mitochondrial complex deficiency, as previously reported in other cases [1‐3], eventually leading to reduced glycogen utilization, followed by the conversion of excessive glycogen into fatty acid, which manifested as increased fatty acid levels in the liver and muscle tissue.

To some extent, our observations indicate novel features of this disease. Most of the clinical features, including early onset, muscle weakness, exercise intolerance, neuropathy, and spastic diplegia, were shared with previously reported patients. The manifestation of developmental delay, lactic acidosis, seizure, and gastrointestinal, renal, and liver problems also overlapped with previous cases [1‐3].

There were four COXPD26 patients in previous reports, who all carried two compound heterozygous mutations/deletions in TRMT5. They shared one common deletion, c.312_315del, which leads to a frameshift [2, 3]. In our study, the proband had different compound heterozygous missense mutations of TRMT5: c.881A>C (p.E294A) from her mother and c.1218G>C (p.Q406H) and c.1481C>T (p.T494M) from her father. The parents appeared normal, whereas the proband had a severe syndrome and died from stroke and respiratory failure at the age of 5 years. To the best of our knowledge, these are the first TRMT5 mutations identified in Asian COXPD26 patients. All previous COXPD26 patients had early symptom onset, but the patients lived longer than our proband and had a higher quality of life. Our case presented with severe symptoms at an early age and with different manifestations than the other COXPD26 patients, which may be the result of the genotype identified in this patient. Further analysis is necessary to confirm this hypothesis.

In the present study, medical exome sequencing was used to explore the possible genetic defects resulting in the disease. Compared to whole genome and whole exome sequencing, medical exome sequencing focuses on clinical interpretable regions of genes, which greatly improves the accuracy of sequencing and broadens the spectrum [12]. Given that the phenotype of the proband was much more severe than those in previous reports, we considered whether there was molecular “double trouble” in the patient’s genome. However, we did not find any known copy number variation which was associated with the phenotypes. We excluded any other candidate genes based on our whole exome sequencing results for either of the two reasons.